Acute Kidney Injury
The FDA gave Breakthrough Device designation to the JuxtaFlow RAD to help prevent AKI during cardiothoracic surgery.
Accurate prediction of severe outcomes of acute kidney injury remains challenging.
Opinions differ on the use of no anticoagulation versus regional citrate anticoagulation for treatment of AKI with CKRT.
A baseline creatinine measurement from clinical trial enrollment may not be the best way to detect acute kidney injury.
SGLT-2is are associated with reduced risk of mortality in patients with type 2 diabetes and acute kidney disease.
Patients who have acute kidney injury while hospitalized face increased risk for morbidity and mortality after discharge.
The FDA has granted a Humanitarian Device Exemption Approval Order to the Selective Cytopheretic Device Pediatric.
Patients hospitalized with COVID-19 face increased risk for long-term adverse outcomes such as major adverse kidney events.
Community-acquired acute kidney injury (CA-AKI) is AKI that develops outside of the hospital setting.
More patients in the terlipressin group had a >30% improvement in serum creatinine from baseline than in the placebo group.
Effective blood pressure control following AKI may have beneficial effects on outcomes.
Examining the effect of SGLT2 inhibitors on biomarkers of tubular injury in patients with acute heart failure.
Advertisement
Advertisement
